Factors associated with discordant results between tests in the univariate analysis
| OR (95% CI) | p-value | |
| Age | ||
| <65 years | 1 | 0.92 |
| ≥65 years | 1.05 (0.4–2.71) | |
| Sex | ||
| Female | 1 | 0.92 |
| Male | 1.05 (0.4–2.71) | |
| Type of cancer diagnosis by location | ||
| Haematologic | 0.92 (0.19–4.42) | 0.92 |
| Nonhaematologic# | 1 | |
| Cancer status | ||
| Partial or complete remission | 1 | 0.84 |
| Current management with palliative or curative chemotherapy¶ | 1.67 (0.54–5.18) | |
| Current management with other treatments | 1.81 (0.41–7.98) | |
| Progression, with follow-up | 0.98 (0.19–5.2) | |
| Initial staging, before the beginning of treatment | 1.96 (0.35–11.17) | |
| Scar of BCG vaccine | ||
| Yes | 0.65 (0.25–1.71) | 0.39 |
| No | 1 | |
| Comorbidities associated with immunosuppression | ||
| Treatment with other immunosuppressants | 1.98 (0.69–5.78) | 0.43 |
| Corticosteroid use for >90 days | 4.25 (0.69–26.22) | |
| Insulin-dependent diabetes | 2.83 (0.27–29.9) | |
| History of haematopoietic stem cell transplant | 2.83 (0.27–29.9) | |
| None | 1 | |
| Lymphopenia | ||
| Yes | 0.99 (0.26–3.81) | 0.99 |
| No | 1 |
BCG: bacille Calmette–Guérin. #: nonhaematologic cancers were grouped for analysis; ¶: cases of management with palliative and curative chemotherapy were grouped for analysis.